To date, it is recommended and necessary to look for the status of five genomic molecular biomarkers (EGFR, ALK, ROS1, BRAFV600, NTRK) and of a protein biomarker (PD-L1). However, the short- and more or less long-term emergence of new targeted treatments of genomic alterations on RET...
A Corrigendum to this article was published on 01 December 2017This article has been updatedKey Points Small-cell lung cancer (SCLC) is a deadly cancer associated with smoke exposure that has neuroendocrine (NE) cell properties and is pathologically, molecularly, biologically and clinically very ...
Metabolic reprogramming is a pivotal biological process in which cellular metabolic patterns change to meet the energy demands of increased cell growth and proliferation. In this review, we explore metabolic reprogramming and its impact on fibrotic disea
It is a BiTE that binds both CD19 (consistently found on ALL blasts) and CD3 (on cytotoxic T-cells) facilitating malignant cell lysis [49]. The second bsAB for treatment of cancer, amivantamab, was approved in 2021 for non-small cell lung cancer (NSCLC). Amivantamab targets EGFR and ...
M. et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269–277 (2002). Article CAS PubMed Google Scholar Zhu, H. et al. Oncogenic EGFR signaling ...
Remdesivir is an antiviral medication used to treat coronavirus disease (COVID-19). Do not co-administer with chloroquine or hydroxychloroquine; may reduce remdesivir’s antiviral activity. Common side effects of remdesivir include decrease in estimated glomerular filtration rate (eGFR), decrease in cre...
Some common mutations include EGFR and PDL1 forlung cancer; and BRCA1 and BRCA2 for breast andovarian cancers. Stage, Grade, or Type The “stage” of your cancer is a measure of how far your cancer has spread. The “grade” of your tumor is a measure of how different the cells are...
Today’s trials are much more likely to focus on patients who have been selected to have the greatest odds of responding to the new therapy. That may seem obvious now, but it’s important to appreciate what a big change that is from the early 2000s, when the EGFR inhibitor Tarceva got...
diagnostics Review A Pound of Flesh: What Cachexia Is and What It Is Not Emanuele Berardi 1,2,† , Luca Madaro 3,† , Biliana Lozanoska-Ochser 3, Sergio Adamo 3 , Lieven Thorrez 1 , Marina Bouche 3,* and Dario Coletti 3,4 1 Department of Development and Re...
Saltz LB, Rubin M, Hochster H, et al.: Cetuximab (IMCC225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor(EGFR) [abstract]. Proceedings of the American Society of Clinical Oncology 2001. Alexandria, VA: American...